Trial Profile
Comparative Study Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients Undergoing Breast Surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Palonosetron (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 06 Aug 2018 Status changed from recruiting to completed.
- 25 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 25 Aug 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.